According to a recent study, infants with an aggressive form of acute lymphoblastic leukemia( ALL ) had significantly higher survival rates after receiving the medication blinatumomab ( Blincyto ) following standard chemotherapy. The treatment may become standard therapy for infants with ALL brought on by KMT2A rearrangements if it is confirmed in larger studies.